실적분석 2026년 8월 3일

Crystal Biotech ($KRYS) Q2 2026 Earnings Analysis — Revenue and Earnings Both Miss Estimates, Shares Plunge After-Hours

Earnings Scorecard

Revenue: $119.22 million (+24% YoY, $122 million estimate) ❌ Miss

EPS: $1.79 diluted ($1.91 estimate) ❌ Miss — the company does not report adjusted results, so this comparison is against GAAP figures

Guidance: Newly issued — 2026 full-year R&D and SG&A combined (excluding stock-based compensation) of $175 million to $195 million

Stock reaction: After-hours -6.48% ($319) — as of 08-03 20:46 KST

Positives

Revenue growth of 24%: Vyjuvek global revenue of $119.22 million in Q2 2026; cumulative post-launch sales of $965.90 million

95% gross margin: Cost of revenue limited to just $6.43 million, reflecting exceptionally strong profitability

$1.1 billion in cash: Total equity of $1,359.13 million and debt of just $141.52 million leave the balance sheet essentially unburdened

Crystal Biotech is the company behind Vyjuvek, a gene therapy that treats dystrophic epidermolysis bullosa (DEB), a rare genetic disorder. This quarter, Vyjuvek revenue reached $119.22 million, up 24% from $96.04 million in the prior-year period, with first-half cumulative sales totaling $235.58 million. The company reported more than 730 insurance reimbursement approvals and more than 640 prescribing physicians, demonstrating that revenue is not a one-time launch surge but is establishing itself as repeat prescriptions for lifelong wound management.

Profitability metrics are even more striking. The 95% gross margin supported operating income of $58.42 million in Q2 2026, and net income climbed 43% to $54.77 million from $38.33 million a year earlier. R&D expense was $14.52 million, essentially flat year-over-year, preserving the structure in which the bulk of incremental revenue drops to the bottom line.

The pipeline calendar is also tightly packed. KB803, a therapy for corneal damage, has completed pivotal trial enrollment with topline results expected in Q4, while KB407 for cystic fibrosis and KB111 for Hailey-Hailey disease are slated for interim data later this year. Inhaled KB707 for lung cancer showed a 31% objective response rate in combination with an immune checkpoint inhibitor. On top of that, launches in Spain and Italy as well as regulatory filings in Switzerland and Australia are slated for the second half.

Negatives

Revenue and earnings both miss: Revenue fell roughly 2% short of consensus, and diluted EPS of $1.79 also trailed the $1.91 estimate

SG&A up 13.6%: $39.85 million, lower than the revenue growth rate but rising quickly in contrast to R&D

European pricing negotiations delayed: Germany negotiations extend into the second half, while France stretches into 2027

The most painful point is the consensus miss. A 24% growth rate is by no means bad in absolute terms, but the bar set by the market for richly valued growth names is the estimate. Revenue of $119.22 million came in roughly $3 million short of the $122 million estimate, and EPS also fell below expectations. However, because the company does not separately report adjusted figures, a one-to-one comparison between an adjusted-basis estimate and a GAAP-basis reported figure is difficult.

Cost structure also warrants a closer look. SG&A rose to $39.85 million, an increase of $4.78 million from $35.07 million in the prior-year period, and on a first-half basis climbed 19% from $67.71 million to $80.86 million. The expense reflects preparation for multi-country European launches, and the direction itself is understandable, but it is money going out the door into countries that have not yet generated revenue.

Monetizing Europe, the next leg of growth, will take time. Pricing and reimbursement negotiations in Germany and France are expected to continue into the second half and 2027, respectively, while the UK has only just begun its negotiations. The only countries the company is confident of launching within the year are Spain and Italy. In addition, revenue effectively comes from Vyjuvek alone, with the rest of the pipeline still in clinical stages, meaning additional time is needed before they contribute to results.

What Management Said

The only quantitative guidance the company provided this time is 2026 full-year R&D and SG&A combined, excluding stock-based compensation. No revenue or profit guidance was given, and there was no prior-quarter baseline for the same line items, so there is no benchmark against which to judge an upward or downward revision. Setting an explicit ceiling on costs is read as a signal that spending will remain disciplined even during the expansion phase.

Management's tone carried more weight on the transformation narrative than on the quarterly numbers. Chairman and CEO Chris Krishnan described the next 12 to 18 months as a potential pivotal turning point from a single commercial success story to a multi-product gene therapy company. In other words, the message is that the clinical readouts concentrated in the second half, rather than a few million dollars of quarterly revenue shortfall, will determine the company's next leg of value. The market, however, graded the numbers first.

Market Reaction and What to Watch

The reason shares fell in after-hours trading is straightforward. Despite a 24% growth rate and a 95% margin, both revenue and EPS came in below consensus. A company with a roughly $10 billion market capitalization and quarterly net income of $54.77 million faces a heavier valuation burden if its growth rate slows even slightly. In particular, this quarter's revenue grew just 2.5% versus the prior quarter ($116.36 million), fueling the interpretation that the U.S. market has entered a maturation phase.

On the flip side, what was damaged in this report was the bar, not the underlying business health. Cash stands at $1.1 billion against debt of just $141.52 million, and the second half is slated to deliver topline results from the corneal damage pivotal trial, two interim readouts, and launches in Spain and Italy. The variables most likely to move the stock going forward are these clinical readouts rather than a few million dollars of quarterly revenue.

Whether topline results from the KB803 (corneal damage) pivotal trial scheduled for Q4 succeed

Whether Spain and Italy actually launch within the year, and progress in pricing negotiations with Germany and France

Whether U.S. revenue growth reaccelerates sequentially or settles into a maturation phase

Whether the pace of SG&A growth stays within the full-year guidance range of $175 million to $195 million